Abstract Body

Vertical transmission of HIV and hepatitis B virus (HBV) is preventable, and risk is reduced through routine antenatal screening coupled with treatment during pregnancy for all women with HIV and those with high HBV viral loads.  This approach is a “double dividend” for HIV, as it provides the opportunity for pregnant women to receive treatment for their own health, while at the same time preventing vertical transmission.  The number of new HIV infections in children is declining, but the global incidence of chronic hepatitis B is still largely driven by vertical and early childhood infections, and challenges remain in implementing HIV and HBV prevention and treatment strategies in pregnant women and infants in some high burden countries.

There are important differences between vertical transmission of HCV, and HIV and HBV, most notably that HCV is not associated with high infant mortality (unlike HIV), there is no vaccine (unlike HBV), and HCV is curable (unlike HIV and HBV).  Efforts are being made to scale up HCV treatment worldwide, and there are ambitious HCV elimination goals.  However, pregnant and breastfeeding women and their infants have been left behind in the HCV elimination agenda, as no direct acting antivirals are licensed for use in these groups.  This is partly due to uncertainty regarding optimal test and treat strategies, with a weak evidence base, and many countries know little about the epidemiology of HCV in pregnant women due to the scarcity of universal antenatal HCV screening.  In this talk the evidence for the effect of HCV on pregnancy and neonatal outcomes, risk of vertical transmission, potential interventions to prevent transmission, safety profiles of DAAs, screening and linkage to care for mothers and HCV diagnosis and treatment for children, will be reviewed.  Key gaps in knowledge and areas for future research will be identified.  There is a need to improve our understanding of the potential benefits associated with routine HCV screening and treatment in these vulnerable populations, to ensure that the double dividend approach of treatment and prevention is used in the most effective way.  Fast-forwarding to the future, if we are serious about HCV elimination then we cannot neglect the potential opportunities of universal antenatal screening to treat mothers and prevent vertical transmission.  We need to learn from our experience with HIV and HBV and accelerate our response.  Otherwise, will it be déjà vu all over again?